Financial Data and Key Metrics Changes - Milestone Pharmaceuticals reported $1.5 million in revenue for Q4 2025, with no revenue comparables in 2024, reflecting earnings under a licensing collaboration agreement following FDA approval of CARDAMYST [21] - R&D expenses for Q4 2025 were $5.5 million, up from $3.9 million in Q4 2024, with full-year R&D expenses at $18.1 million compared to $14.4 million in 2024 [21][22] - G&A expenses increased to $5.1 million in Q4 2025 from $4.0 million in the prior quarter, with full-year G&A expenses at $17.3 million compared to $16.7 million in 2024 [22][23] - Commercial expenses surged to $8.2 million in Q4 2025 from $4.4 million in Q4 2024, with full-year commercial expenses at $28.3 million compared to $11 million in 2024 [23] - The net loss for Q4 2025 was $17.4 million or $0.16 per share, compared to a net loss of $12.4 million or $0.19 per share in Q4 2024 [24] - As of December 31, 2025, the company had $106 million in cash equivalents and short-term investments, with a pro forma cash figure of approximately $200 million after subsequent financing activities [24][25] Business Line Data and Key Metrics Changes - The launch of CARDAMYST, an etripamil nasal spray for PSVT, marks a significant new therapeutic option for over 2 million patients, with the commercial strategy focused on driving new patient starts and achieving commercial coverage [5][7] - The commercial team has begun executing the launch strategy, with CARDAMYST available in retail pharmacies within six weeks of FDA approval [12][13] Market Data and Key Metrics Changes - The company is targeting around 10,000 healthcare providers who manage half of the 1 million patients with PSVT expected to receive treatment in 2026 [12] - Initial feedback from prescribers has been positive, with over 150 prescriptions filled in the first month, primarily from new patient starts [16][20] Company Strategy and Development Direction - The FDA approval of CARDAMYST is seen as a foundation for value creation, with plans to leverage clinical data for marketing approvals in other regions, including Europe [9] - The company aims to establish a strong commercial franchise in acute cardiovascular therapy, focusing on making CARDAMYST accessible and affordable for patients [20][26] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the early launch phase, noting that while it is too early to identify durable patterns, they expect prescription volume to increase and commercial coverage to expand over time [20][26] - The company is actively engaging with payers to demonstrate the value of CARDAMYST, aiming for broad coverage while managing the natural dampening effect of reimbursement processes [53][54] Other Important Information - The company has enhanced its leadership team with the addition of David Sandoval as General Counsel and Chief Compliance Officer, expected to support long-term growth [10] Q&A Session Summary Question: Feedback on CARDAMYST launch and coverage denial reasons - Management noted broad adoption across cardiology and electrophysiology, with APPs being key prescribers; coverage denials are primarily due to paperwork requirements for patient eligibility [28][31] Question: Reimbursement timelines and patient access - Management indicated that scripts are being filled within days to weeks once the system is engaged, with ongoing efforts to support patients during the reimbursement process [35][38] Question: Current prescribing trends and patient demographics - Management reported a diverse patient mix, with some using CARDAMYST before ablation or as a routine course; they are optimistic about the drug's broad applicability [46][48] Question: Contracting strategy and formulary positioning - The company aims for open access with reasonable prior authorization requirements, expecting a 50/50 split between commercial and Medicare coverage [58][61]

Financial Data and Key Metrics Changes - Milestone Pharmaceuticals reported $1.5 million in revenue for Q4 2025, with no revenue comparables in 2024, reflecting earnings under a licensing collaboration agreement following FDA approval of CARDAMYST [21] - R&D expenses for Q4 2025 were $5.5 million, up from $3.9 million in Q4 2024, with full-year R&D expenses at $18.1 million compared to $14.4 million in 2024 [21][22] - G&A expenses increased to $5.1 million in Q4 2025 from $4.0 million in the prior quarter, with full-year G&A expenses at $17.3 million compared to $16.7 million in 2024 [22][23] - Commercial expenses surged to $8.2 million in Q4 2025 from $4.4 million in Q4 2024, with full-year commercial expenses at $28.3 million compared to $11 million in 2024 [23] - The net loss for Q4 2025 was $17.4 million or $0.16 per share, compared to a net loss of $12.4 million or $0.19 per share in Q4 2024, with a full-year net loss of $63.1 million or $0.75 per share compared to $41.5 million or $0.67 per share in 2024 [24] Business Line Data and Key Metrics Changes - The launch of CARDAMYST, an etripamil nasal spray for PSVT, marks a significant new therapeutic option for over 2 million patients, with the commercial strategy focused on driving new patient starts and achieving commercial coverage [5][7] - The commercial team has engaged with approximately 10,000 providers who manage half of the 1 million patients expected to receive treatment for PSVT in 2026 [12] Market Data and Key Metrics Changes - The PSVT market is identified as a clearly defined opportunity within cardiovascular specialty pharma, with efforts to demonstrate the value proposition of CARDAMYST to payers [13] - Initial feedback from prescribers has been positive, with over 150 prescriptions filled in the first month of launch, primarily from new patient starts [16] Company Strategy and Development Direction - The FDA approval of CARDAMYST is seen as a foundation for value creation, with plans to leverage clinical data for marketing approvals in other regions, including Europe [8][9] - The company aims to establish a strong commercial franchise and reduce reliance on emergency department care through the self-administered CARDAMYST [26] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the early launch phase, noting that while it is too early to identify durable patterns, they expect prescription volume to increase and commercial coverage to expand over time [20] - The company is focused on ensuring that physicians can prescribe CARDAMYST, patients can access it, and payers recognize the demand in the marketplace [20] Other Important Information - The company reported a pro forma cash figure of approximately $200 million, supporting the successful launch of CARDAMYST and providing an operating runway into late 2027 [10][24] - The leadership team has been enhanced with the addition of David Sandoval as General Counsel and Chief Compliance Officer [10] Q&A Session Summary Question: Feedback on CARDAMYST launch and coverage denial reasons - Management noted broad adoption among cardiologists and advanced practice providers, with coverage denials primarily due to paperwork requirements for patient eligibility [28][31] Question: Reimbursement timelines and patient access - Management indicated that scripts are being filled within days to weeks after engaging the system, with ongoing efforts to support patients during the reimbursement process [35][38] Question: Replacement therapies for CARDAMYST and patient feedback - Management reported a broad range of patients using CARDAMYST, including those awaiting ablation, with positive early feedback from social media indicating excitement about having the treatment available [46][49] Question: Contracting strategy and formulary positioning - Management aims for open access with reasonable coverage terms, expecting a 50/50 split between commercial and Medicare patients, and is actively engaging payers for coverage [58][61]